跳轉至內容
Merck
全部照片(1)

重要文件

1535008

USP

苯妥英

United States Pharmacopeia (USP) Reference Standard

同義詞:

5,5-二苯基海因, 5,5-联苯基乙内酰脲, 苯妥英

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H12N2O2
CAS號碼:
分子量::
252.27
Beilstein:
384532
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

phenytoin

製造商/商標名

USP

mp

293-295 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

O=C1NC(=O)C(N1)(c2ccccc2)c3ccccc3

InChI

1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)

InChI 密鑰

CXOFVDLJLONNDW-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Phenytoin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Phenytoin Sodium
  • Phenytoin Chewable Tablets
  • Phenytoin Oral Suspension
  • Phenytoin Sodium Injection
  • Extended Phenytoin Sodium Capsules
  • Phenytoin Compounded Topical Gel
  • Fosphenytoin Sodium Injection

生化/生理作用

减少癫痫大发作的发生率;可能通过 Na+、K+ 和 Ca2+ 通道的影响而稳定可兴奋膜。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 4 Oral - Carc. 2 - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Deborah Pugin et al.
Critical care (London, England), 18(3), R103-R103 (2014-06-03)
Seizures refractory to third-line therapy are also labeled super-refractory status epilepticus (SRSE). These seizures are extremely difficult to control and associated with poor outcome. We aimed to characterize efficacy and side-effects of continuous infusions of pentobarbital (cIV-PTB) treating SRSE. We
Chunhong Shen et al.
Bone, 64, 246-253 (2014-05-02)
It has been shown that antiepileptic drugs (AEDs) may have a detrimental effect on bone health and translate into an increased risk of bone fracture. We aimed to comprehensively evaluate the association between use of AEDs and fracture risk. We
Syed Nabeel Zafar et al.
BMC neurology, 12, 30-30 (2012-05-31)
Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in
Lelia Duley et al.
The Cochrane database of systematic reviews, (10)(10), CD000128-CD000128 (2010-10-12)
Eclampsia, the occurrence of a seizure in association with pre-eclampsia, remains a rare but serious complication of pregnancy. A number of different anticonvulsants have been used to control eclamptic fits and to prevent further seizures. The objective of this review
P J Smith et al.
Endocrine reviews, 5(4), 514-524 (1984-01-01)
The studies described above indicate the likelihood of a significant effect of DPH on cellular functions that are regulated by T3 at concentrations of DPH that occur during treatment of patients with Dilantin. Thus, it is possible that sensitive measures

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務